High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus

Circulation

Volumn 119, Issue 15, 2009, Pages 2103-2111

  Drew, Brian G ^a,b   Duffy, Stephen J ^a   Formosa, Melissa F ^a   Natoli, Alaina K ^a   Henstridge, Darren C ^a,b   Penfold, Sally A ^a   Thomas, Walter G ^a   Mukhamedova, Nigora ^a   De Courten, Barbora ^a   Forbes, Josephine M ^a   Yap, Felicia Y ^a   Kaye, David M ^a   Ven Hall, Gerrit ^c   Febbraio, Mark A ^a   Kemp, Bruce E ^d,e   Sviridov, Dmitri ^a   Steinberg, Gregory R ^d   Kingwell, Bronwyn A ^a,f  

^a IDI Heart and Diabetes Institute   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e CSIRO   (Australia)

^f Baker Heart and Diabetes Institute   (Australia)

Author keywords

Glucose; Insulin; Lipoproteins; Metabolism; Muscles

Indexed keywords

ABC TRANSPORTER A1; ACETYL COA CARBOXYLASE BETA; ACETYL COENZYME A CARBOXYLASE; APOLIPOPROTEIN A1; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; PLACEBO; RECONSTITUTED HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG; ABC TRANSPORTER; FATTY ACID; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PHENFORMIN;

ADULT; ANIMAL CELL; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; MUSCLE BIOPSY; MUSCLE FIBER CULTURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TREATMENT OUTCOME; ANIMAL; BLOOD; CALCIUM SIGNALING; CELL CULTURE; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; MUSCLE CELL; PANCREAS ISLET; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SECRETION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOLIPOPROTEIN A-I; ATP-BINDING CASSETTE TRANSPORTERS; CALCIUM SIGNALING; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CELLS, CULTURED; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FATTY ACIDS; FEMALE; GLUCOSE; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; ISLETS OF LANGERHANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MICE; MIDDLE AGED; MUSCLE CELLS; MUSCLE, SKELETAL; PHENFORMIN; SIGNAL TRANSDUCTION;

EID: 65449178091     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.843219     Document Type: Article

References (39)

1. Gordon DJ, Rifkind BM. High-density lipoprotein: the clinical implications of recent studies. N EnglJ Med. 1989;321:1311-1316.
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
3. Hoang A, Murphy AJ, Coughlan MT, Thomas MC, Forbes JM, O'Brien R, Cooper ME, Chin-Dusting JP, Sviridov D. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia. 2007;50:1770-1779.
4. Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, Bales CW, Henes S, Samsa GP, Otvos JD, Kulkarni KR, Slentz CA. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002;347:1483-1492.
5. Abderrahmani A, Niederhauser G, Favre D, Abdelli S, Ferdaoussi M, Yang JY, Regazzi R, Widmann C, Waeber G. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia. 2007;50:1304-1314.
6. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med. 2007;13:340-347.
7. Han R, Lai R, Ding Q, Wang Z, Luo X, Zhang Y, Cui G, He J, Liu W, Chen Y. Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia. 2007;50:1960-1968.
8. Drew BG, Fidge NH, Gallon-Beaumier G, Kemp BE, Kingwell BA. High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc Natl Acad Sci USA. 2004;101:6999-7004.
9. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1:15-25.
10. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300.
11. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodes-Cabau J. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297: 1675-1682.
12. Nieuwdorp M, Vergeer M, Bisoendial RJ, op't Roodt J, Levels H, Birjmohun RS, Kuivenhoven JA, Basser R, Rabelink TJ, Kastelein JJ, Stroes ES. Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus. Diabetologia. 2008;51:1081-1084.
13. Blau HM, Webster C. Isolation and characterization of human muscle
14. cells. Proc Natl Acad Sci U S A. 1981;78:5623-5627.
15. Chen MB, McAinch AJ, Macaulay SL, Castelli LA, O'Brien PE, Dixon JB, Cameron-Smith D, Kemp BE, Steinberg GR. Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J Clin Endocrinol Metab. 2005;90:3665-3672.
16. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes. 2006;55:2688-2697.
17. Woods A, Azzout-Marniche D, Foretz M, Stein SC, Lemarchand P, Ferre P, Foufelle F, Carling D. Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol. 2000;20:6704-6711.
18. Mukhamedova N, Fu Y, Bukrinsky M, Remaley AT, Sviridov D. The role of different regions of ATP-binding cassette transporter A1 in cholesterol efflux. Biochemistry. 2007;46:9388-9398.
19. McConell GK, Lee-Young RS, Chen ZP, Stepto NK, Huynh NN, Stephens TJ, Canny BJ, Kemp BE. Short-term exercise training in humans reduces AMPK signalling during prolonged exercise independent of muscle glycogen. J Physiol. 2005;568:665-676.
20. Chen ZP, Stephens TJ, Murthy S, Canny BJ, Hargreaves M, Witters LA, Kemp BE, McConell GK. Effect of exercise intensity on skeletal muscle AMPK signaling in humans. Diabetes. 2003;52:2205-2212.
21. Muscat GE, Wagner BL, Hou J, Tangirala RK, Bischoff ED, Rohde P, Petrowski M, Li J, Shao G, Macondray G, Schulman IG. Regulation of cholesterol homeostasis and lipid metabolism in skeletal muscle by liver X receptors. J Biol Chem. 2002;277:40722-40728.
22. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care. 1997;20:1087-1092.
23. Guyard-Dangremont V, Desrumaux C, Gambert P, Lallemant C, Lagrost L. Phospholipid and cholesteryl ester transfer activities in plasma from 14 vertebrate species: relation to atherogenesis susceptibility. Comp Biochem Physiol B Biochem Mol Biol. 1998;120:517-525.
24. Nishina PM, Lowe S, Wang J, Paigen B. Characterization of plasma lipids in genetically obese mice: the mutants obese, diabetes, fat, tubby, and lethal yellow. Metabolism. 1994;43:549-553.
25. Fujii N, Hayashi T, Hirshman MF, Smith JT, Habinowski SA, Kaijser L, Mu J, Ljungqvist O, Birnbaum MJ, Witters LA, Thorell A, Goodyear LJ. Exercise induces isoform-specific increase in 5'AMP-activated protein kinase activity in human skeletal muscle. Biochem Biophys Res Commun. 2000;273:1150-1155.
26. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002;415:339 -343.
27. Cavelier C, Rohrer L, von Eckardstein A. ATP-binding cassette transporter A1 modulates apolipoprotein A-I transcytosis through aortic en-dothelial cells. Circ Res. 2006;99:1060-1066.
28. Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B, Schafers M, Fobker M, Zidek W, Assmann G, Chun J, Levkau B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004;113:569-581.
29. Jensen TE, Rose AJ, Jorgensen SB, Brandt N, Schjerling P, Wojtaszewski JF, Richter EA. Possible CaMKK-dependent regulation of AMPK phosphorylation and glucose uptake at the onset of mild tetanic skeletal muscle contraction. Am J Physiol. 2007;292:E1308-E1317.
30. Rose AJ, Kiens B, Richter EA. Ca2 + -calmodulin-dependent protein kinase expression and signalling in skeletal muscle during exercise. J Physiol. 2006;574:889 -903.
31. Richter EA. Glucose utilization. In: Rowe LB, Shepherd JT, eds. Handbook of Physiology: Section 12: Exercise: Regulation and Integration of Multiple Systems. New York, NY: Oxford University Press; 1996:870 -911.
32. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990;263:2893-2898.
33. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357-362.
34. Sonmez A, Baykal Y, Kilic M, Yilmaz MI, Saglam K, Bulucu F, Kocar IH. Fluvastatin improves insulin resistance in nondiabetic dyslipidemic patients. Endocrine. 2003;22:151-154.
35. Jula A, Marniemi J, Huupponen R, Virtanen A, Rastas M, Ronnemaa T. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA. 2002; 287:598-605.
36. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004;109:2197-2202.
37. Kodama S, Tanaka S, Saito K, Shu M, Sone Y, Onitake F, Suzuki E, Shimano H, Yamamoto S, Kondo K, Ohashi Y, Yamada N, Sone H. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med. 2007;167: 999 -1008.
38. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357: 2109-2122.
39. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJ. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 2002;105: 2159-2165.